Certara, Inc. (CERT)
Market Cap | 1.83B |
Revenue (ttm) | 372.80M |
Net Income (ttm) | -31.08M |
Shares Out | 160.97M |
EPS (ttm) | -0.20 |
PE Ratio | n/a |
Forward PE | 22.90 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,171,580 |
Open | 11.62 |
Previous Close | 11.60 |
Day's Range | 11.05 - 11.68 |
52-Week Range | 9.41 - 19.87 |
Beta | 1.53 |
Analysts | Buy |
Price Target | 15.92 (+40.02%) |
Earnings Date | Nov 6, 2024 |
About CERT
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new dr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $15.92, which is an increase of 40.02% from the latest price.
News
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researc...
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
Certara Reports Third Quarter 2024 Financial Results
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye...
Certara to Participate in the Stephens Annual Investment Conference
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephen...
Certara Appoints John Reynders as New Independent Board Member
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of ...
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third qu...
Certara Completes Acquisition of Chemaxon
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon
The final trades of the day with the Fast Money traders.
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi...
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive ...
Certara Reports Second Quarter 2024 Financial Results
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y...
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), ...
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q...
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
Certara to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcar...
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Co...
Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher -...
Certara Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024...
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara Reports Fourth Quarter 2023 Financial Results
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and ful...